FDA awards grant for cancer drug study

The US FDA has awarded a $1.6m grant under its orphan drugs programme to a Alabama-based biotech company Egen to help the company with clinical trials of a potential new therapy for ovarian cancer

The US Food and Drug Administration (FDA) has awarded a $1.6m grant under its orphan drugs programme to a small, Alabama-based biotech company called Egen to help the company with clinical trials of a potential new therapy for ovarian cancer.

The four-year grant is intended to assist in the phase II clinical development of the privately held company's lead product, Egen-001, which is being developed for the treatment of advanced recurrent ovarian cancer.

The drug is an interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 enhances the body's immune system against cancer and inhibits tumour blood supply, according to Egen.

The product has completed two phase I trials: one as monotherapy in platinum-resistant ovarian cancer patients, and the other in combination with carboplatin/docetaxel chemotherapy in platinum-sensitive ovarian cancer patients.

The FDA granted orphan drug status to Egen-001 in 2005. The status, which is reserved for drugs intended to treat diseases that affect fewer than 200,000 Americans, carries a number of benefits, including seven years of US marketing exclusivity, tax breaks and eligibility for help with clinical trial costs.

This is Egen's second grant for the drug from the FDA. The first, totaling $1m, was awarded in 2005.

3rd February 2011

PME Digital Edition

Featured jobs

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager / Account Director: Great salary and bebefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Programme Executive: Salary TBC

Scientific Director: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer: Great salary and benefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Medical Writer - (London, Brighton or Copenhagen): Competitive

Senior Account Manager or AD - Medical Communications: Salary TBC

Account Manager – Med Comms – London: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Pharma’s isolated islands of innovation: With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit: What does it mean for the life science sector?...
The Holy Grail of HCP Access: This is the data you need to gain access....